Skip to main content

Monitoring the immune response mediated by cd4+ t cells in vaccinated cancer patients.

Objective

There is no sensitive and reliable method to monitor the immune response in the cancer patients vaccinated with a protein or with peptides presented by HLA class II molecules. We will therefore analyse in responding patients if we find a difference in terms of number, specificity, or diversity between anti-MAGE-3 CD4+ T cells before and after vaccination.

Funding Scheme

RGI - Research grants (individual fellowships)

Coordinator

CHRISTIAN DE DUVE INSTITUTE OF CELLULAR PATHOLOGY
Address
Avenue Hippocrate 74
1200 Bruxelles
Belgium